EO-14401
Accelerating Medical Treatments for Serious Mental Illness
- Signed
- Apr 18, 2026
- Published
- Apr 22, 2026
Federal Register: 2026-07907
Source: Federal Register.
Accelerating Psychedelic Drug Research and Access for Mental Illness
What it does
This order directs federal agencies to speed up the review, approval, and access pathways for psychedelic drugs — including ibogaine compounds — as treatments for serious mental illnesses such as major depressive disorder and substance use disorder. It instructs the FDA to assign priority review vouchers to qualifying psychedelic drugs, establishes a Right to Try pathway for eligible patients, allocates at least $50 million from existing funds through ARPA-H for federal-state collaboration, and directs the FDA, HHS, and VA to share clinical trial data. It also directs the Attorney General to initiate rescheduling reviews for any psychedelic substance that completes Phase 3 clinical trials and receives FDA approval.
Who benefits
Adults with treatment-resistant serious mental illnesses (estimated 14 million+). Veterans, who experience suicide rates more than twice the non-veteran adult population. Patients with major depressive disorder or substance use disorder who have not responded to standard therapies. Researchers and clinical trial sponsors working on psychedelic therapeutics. States that have already enacted or are developing psychedelic treatment programs (e.g., Oregon, Colorado). Pharmaceutical companies developing psychedelic-based drugs. Physicians seeking legal pathways to administer these treatments.
Who is affected
Patients who may access experimental treatments with incompletely understood long-term safety profiles. Communities and families concerned about broader normalization of Schedule I substances. Drug enforcement agencies and personnel whose regulatory workload and authority would shift. Existing mental health treatment providers whose standard-of-care practices could be disrupted. Taxpayers, as $50 million in existing ARPA-H funds would be redirected. States that have not enacted psychedelic programs, which may face pressure to develop them to access federal funding. Insurance and payer systems that may face new coverage questions for novel treatments.
Supporters argue
Supporters argue that the scale of the serious mental illness and veteran suicide crisis — with over 6,000 veteran suicides annually and 14 million adults affected — justifies accelerating access to treatments that have already received FDA Breakthrough Therapy designation, a rigorous scientific threshold. They contend the order works within existing legal frameworks (the Right to Try Act, the Controlled Substances Act's rescheduling process, and the Federal Food, Drug, and Cosmetic Act) rather than bypassing them, and that the president's Article II authority to direct executive agencies to prioritize and coordinate their statutory functions is well-established.
Opponents argue
Opponents argue that accelerating approval timelines and expanding access to Schedule I substances before full safety and efficacy data are available could expose vulnerable patients — including those with serious mental illness — to unknown long-term harms. They contend that the Right to Try Act was designed for terminal illness, not mental health conditions, and that extending it to psychedelics may stretch the statute beyond its intended scope, raising questions under the major-questions doctrine given the vast economic and public health significance of rescheduling controlled substances without explicit congressional authorization.
Constitutional basis
Executive orders rest on constitutional authority or statutory delegation. This summary describes the legal grounding cited or implied by the order.
The order invokes the president's Article II Take Care Clause authority (Art. II, §3) to direct executive agencies to implement existing statutes. It operates under statutory delegations including the Right to Try Act (21 U.S.C. §360bbb-0a), the Controlled Substances Act rescheduling authority (21 U.S.C. §811, §823), and the Federal Food, Drug, and Cosmetic Act (§505). Post-Loper Bright (2024), courts would independently review whether agency actions taken under this order fall within the bounds of those statutory delegations, and the major-questions doctrine (West Virginia v. EPA, 2022) could be invoked if rescheduling decisions are challenged as lacking clear congressional authorization.